Monash University's pioneering mRNA vaccine research

Leading the way in innovative mRNA vaccine research, Monash University contributes to global health by reducing mortality from infectious diseases and improving health outcomes:

  • The Biomedicine Discovery Institute and the Faculty of Medicine, Nursing and Health Sciences are developing a universal influenza vaccine using mRNA technology, aiming to provide broader and longer-lasting immunity against diverse influenza strains.
  • The Monash Institute of Pharmaceutical Sciences, in collaboration with the Peter Doherty Institute, is developing Australia's first mRNA COVID-19 vaccine candidate, addressing 'immune imprinting' and showing stronger antibody responses to Omicron variants.
  • The launch of the Moderna Technology Centre at Monash's Clayton campus will produce up to 100 million vaccine doses annually, enhancing access to vaccines for COVID-19, influenza, and RSV.
  • Researchers led by Professor Tony Purcell and Dr. Asolina Braun have identified over 200 new vaccine target candidates from SARS-CoV-2, potentially leading to vaccines with longer-lasting and broader immunity.

    • Opening of Moderna Technology Centre

  • The Monash Ramaciotti Centre for Cryo-Electron Microscopy, in collaboration with the University of Oxford, has solved the structure of the T cell receptor on γδ T cells, enhancing understanding of immune responses and supporting immunotherapy and vaccine development.

Related SDGs

SDG 9 Industry, Innovation and Infrastructure SDG 17 Partnerships For The Goals